prednisone,nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', 'ipi/', 'prednisone', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo', 'cosmic-313']
updated cosmic-313 analysis (+5 mo f/u)
ph3 1l ipi/nivo +/- cabo in imdc int/poor risk itt pop: med pfs 15.3 vs 11.3 mo (hr 0.74) int: 17.9 vs 11.3 mo (hr 0.68) poor: 9.5 vs 11.2 mo (hr 0.93) aes leading to drug d/c int risk subgroup os data pending
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology